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A B S T R A C T
Introduction: Acute pulmonary thromboembolism (PTE) is a life-threatening disease. Mortality in PTE
still remains very high in spite of progress in diagnostic tools. Mortality rate is about 30% in patients with
unrecognized acute PTE.
Methods: It is a single center observational study of 31 consecutive patients who were hospitalized in
the Department of Cardiology at MS Ramaiah Memorial hospital between January 1, 2010 and June
2015. All the patients conﬁrmed with diagnosis of acute PTE by CT scan (either HRCT or CTPA) were
included in the study. Following relevant investigations chosen patients were risk stratiﬁed as per
standard guidelines into massive, sub massive or low risk and treated accordingly. The included patients
were followed up for a period of 1 year with 2D-echocardiogram and other relevant investigations for
comparison to assess improvement. Mortality due to either acute PTE or other causes was noted in the
study.
Results: Of the 31 patients enrolled in our study, 71% (n = 22) of the patients belonged to the age range
20–50 years with those in the age group 31–40 years comprising 39% (n = 12) of the total. Elderly people
over 65 years of age comprised only 19% (n = 6) of the total number of patients. Dyslipidemia, prolonged
immobilization, deep vein thrombosis, post-operative state, malignancy and post-partum period were
the commonly reported risk factors. We thrombolysed a total of 18 (58%) patients with massive and
submassive PTE, of which 12 (39%) received tenecteplase and 6 patients received streptokinase (19%).
Three (9%) patients required repeat thrombolysis with streptokinase due to failed thrombolytic therapy
with tenecteplase.
Conclusions: Our study reported higher incidence of acute PTE in the middle age group population.
Prevalence of dyslipidemia was high in this cohort of patients studied although the exact association of it
in APE could not be determined. Thrombolytic therapy can be considered for patients with both massive
and submassive pulmonary thromboembolism. Repeat thrombolysis can be considered in case one
thrombolytic agent failed to give the desirable results.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Acute pulmonary embolism (PE) is a common and potentially
lethal form of venous thromboembolism (VTE) which is commonly
encountered in clinical practice. Most patients die of this fatal
condition usually within the ﬁrst 1 h of the event with mortality
rate reaching nearly 10% during this period.1 Mortality rate of* Corresponding author at: Department of Cardiology, MS Ramaiah Memorial
Hospital, MSRIT Post, Bangalore, Karnataka 560054, India.
E-mail address: nmalesh@yahoo.co.in (U.M. Nagamalesh).
Please cite this article in press as: Nagamalesh UM, et al. Acute pulmon
outcome – A single center experience, Indian Heart J. (2016), http://
http://dx.doi.org/10.1016/j.ihj.2016.08.010
0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).diagnosed and treated pulmonary embolism ranges from 3 to 8%,
but increases to about 30% in untreated pulmonary embolism.1 In
the United States, acute pulmonary embolism afﬂicts 500,000–
600,000 persons annually and is either a primary or secondary
cause of death in 150,000–200,000 of these individuals.2 The
1-year mortality rate in the PIOPED study was reported as 25%,
with 2.5% dying from primary cause as pulmonary embolism
itself.3 Other studies have reported that in patients without
preexisting cardiac or pulmonary disease, the 1-year mortality rate
ranged from 3% to 9%.4,5 Mortality in APE is mainly reported to be
due the associated comorbid conditions like cancer, infections,
cardiovascular diseases, and other pulmonary diseases.6ary thromboembolism: Epidemiology, predictors, and long-term
dx.doi.org/10.1016/j.ihj.2016.08.010
 India. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Age distribution of patients.
Age group Number of patients Percentage (%)
20–30 05 16
31–40 12 39
41–50 05 16
51–60 03 10
>60 06 19
Total 31 100
Fig. 2. Risk factors for APE.
Fig. 1. Sex disribution.
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diagnosis challenging, treatment diverse and results unpredictable
with subsequent high morbidity and mortality. The condition is
often suspected in patients who present with unexplained
dyspnea, tachypnea, or chest pain. Further, a background of high
risk predisposing conditions like malignancy, immobilization,
recent major surgery, orthopedic surgeries and others warrant an
urgent investigation when APE is clinically suspected.
Despite therapeutic and diagnostic advances, the data from
developing countries are largely lacking with respect to diagnostic
and treatment efﬁcacy and also there is insufﬁcient data of long-
term follow-up of those treated.
Our study was conducted to understand the clinical proﬁle of
patients with APE and its response to standard guideline based
treatment. Further, the patients who were successfully treated
were followed up long-term to understand the overall long-term
beneﬁt achieved.
2. Methods
It was a single center observational study conducted at MS
Ramaiah Memorial hospital. The study began in January 2010 and
recruitment of patients concluded on June 2014. However, data
collection on long-term follow-up concluded on June 2015, i.e.,
after 1 year of the last date of recruitment period.
All the patients with clinically suspected APE were assessed
with Well’s Criteria. Those with likely APE on Well’s criteria were
investigated further with D-dimer testing and diagnosis of APE
was ﬁnally conﬁrmed by CT scan (either HRCT or CTPA). Patients
who were admitted in our cardiac intensive care following an
established diagnosis were only included for the study as it
needed close monitoring of treatment response of these patients.
Also it enabled us to study the clinical parameters in greater
detail at baseline and further helped to enroll them for long-term
follow-up. Patients with diagnosis of APE who had already
received treatment before reaching the study center, those
with previous diagnosis of Acute PTE irrespective of their
current treatment status, patients with suspected diagnosis of
APE who died before a diagnosis could be established, those who
did not consent for CT imaging and patients with non-availability
of baseline data or long-term follow-up data were again
excluded.
A total of 38 patients with suspected PTE were identiﬁed during
the study period. Out of this, two patients did not consent for
enrollment. Five patients were critically ill with signiﬁcant co-
morbidities (mainly renal dysfunction) which made them unsuit-
able for CTPA and were treated on the basis of clinical suspicion
only. After satisfying the necessary criteria we were able to recruit
31 patients during the study period. A detailed record of clinical
proﬁle of all the patients included in the study was done. Baseline
record of following investigations were made in common in all
patients: complete hemogram, renal function tests, serum
electrolyte assay, liver function tests, fasting lipid proﬁle, thyroid
proﬁle, coagulation proﬁle, ECG, 2D-echocardiogram, ultrasonog-
raphy of abdomen and chest X-ray. Additional investigations were
done as deemed necessary for identiﬁcation of etiology and/or
complications in speciﬁc group of patients. Chosen patients were
risk stratiﬁed as per standard guidelines into massive, sub massive
or low risk and treated as per current guidelines. The included
patients were followed up for a period of 1 year with 2D-
echocardiogram and other relevant investigations for comparison
to assess improvement. Mortality due to either acute PTE or other
causes was noted in the study.
Statistical analysis was done and continuous variables were
presented as mean, and ordinal variables as percentages.Please cite this article in press as: Nagamalesh UM, et al. Acute pulmon
outcome – A single center experience, Indian Heart J. (2016), http://3. Results
Of the 31 patients enrolled in our study, 71% (n = 22) of the
patients belonged to the age range 20–50 years (Table 1). 39%
(n = 12) of the total belonged to age range 31–40 years. Elderly over
65 years of age comprised 19% (n = 6) of the total. Sex difference
was also noticed with APE being observed to be more common
among male patients (58%) (Fig. 1).
Dyslipidemia, prolonged immobilization, deep vein thrombosis,
post-operative state, malignancy and post-partum period were the
commonly reported risk factors in our study population (Fig. 2).
Dyslipidemia was identiﬁed in 42% (n = 13) of our patients
although the clinical signiﬁcance of dyslipidemia as a risk factor
is yet to be clearly established. 35% (n = 11) of the patients reported
prolonged immobilization prior to the event with over 50% (n = 6)
of them being the elderly over 65 years of age. The reasons for
prolonged immobilization were mainly recent long travels, serious
illnesses, and musculoskeletal causes with the latter being more
commonly reported among the elderly.
Dyspnea was the most common symptom reported at
presentation in all the 31 patients. Additionally reported symp-
toms included palpitations (71%, n = 22) syncope (32%, n = 10) and
chest pain (29%, n = 9) (Fig. 3). The most common clinical sign was
tachycardia (58%, n = 18) and tachypnea (32%, n = 10). Patients
with dyspnea on clinical assessment had NYHA Class II or more
symptoms at presentation. Following treatment when these
patients were reassessed for NYHA functional class at the end ofary thromboembolism: Epidemiology, predictors, and long-term
dx.doi.org/10.1016/j.ihj.2016.08.010
Fig. 3. Clinical features at presentation.
Fig. 5. Classiﬁcation of APE.
Table 3
Complications in ape.
Sl. no. Complications Number (n) Percentage (%)
1 Reversible shock on admission 8 26
2 Mechanical ventilation 3 10
3 Aborted sudden cardiac death 1 3
4 Shock requiring inotropic use 8 26
5 Bleeding 4 13
6 Elevated PA pressure after 1 year 8 26
7 RV dilatation/dysfunction after
1 year
10 32
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ment of their functional class to NYHA Class I. Out of the 35%
(n = 11) patients who were in NYHA Class IV at admission, nearly
81.8% patients (n = 9) showed signiﬁcant improvement of their
functional status to NYHA III or less at 1 year (Table 2; Fig. 4).
2D echocardiography was used for assessing the parameters
like pulmonary artery pressure and RV dilatation. These param-
eters were easily available for comparison during future follow-up.
During follow-up 26% (n = 8) of patients had persistently elevated
pulmonary artery pressure and 32% (n = 10) patients had RV
dilatation even after 1 year of treatment of APE (Table 3). Out of
this, three patients had clinical features of progressive right heart
failure.
In our study all the patients with suspected APE on initial
assessment were subjected to CTPA, Echocardiography and
troponin T. Based on the ﬁndings patients were classiﬁed as
massive, sub-massive and low risk groups.
Acute PE with sustained hypotension with SBP <90 mmHg for
at least 15 min or requiring inotropic support were considered as
massive PTE, which consists of 26% (08) of patients. Submissive PE
patients were those with APE without systemic hypotension (SBP
90 mmHg) but with either RV dysfunction or myocardial
necrosis, which consisted 32% of patients (10). Mild APE formed
the remainder group of patients (41%, n = 13) (Fig. 5).Fig. 4. NYHA class at admission and at 1 year.
Table 2
NYHA class at admission and at 1-year follow-up.
Functional
class
On
admission
Percentage
(%)
After
1 year
Percentage
(%)
NYHA I 00 00 23 74
NYHA II 08 26 03 9
NYHA III 12 39 05 16
NYHA IV 11 35 00 00
Please cite this article in press as: Nagamalesh UM, et al. Acute pulmon
outcome – A single center experience, Indian Heart J. (2016), http://We thrombolysed a total of 18 (58%) patients majority of whom
had massive or submassive PTE, of which 12 (39%) received
tenecteplase and 6 patients received streptokinase (19%). Three
(9%) patients required repeat thrombolysis with streptokinase due
to failed thrombolytic therapy with tenecteplase (Table 4).
In view of persistent elevated PA pressure and early RV
dysfunction two patients underwent pulmonary endarterectomy
after 6 months of index event. They are under follow-up with
normal PA pressure and normal RV function. None of them were
sent for surgical embolectomy. 16% (n = 5) patients were put IVC
Filter after careful clinical assessment to prevent recurrent PE
(Table 5).
Overall reported mortality rate was 6% (n = 2). One patient with
massive pulmonary embolism died in hospital after thrombolysis
due to persistent hypoxia, bleeding and shock. The second patient
died after few weeks at home. He had minor PTE with no DVT and
was on oral anticoagulation. The exact cause of death in him could
not be reached. Overall 52% (n = 16) of the subjects presented with
shock at admission or within 48 h following admission. Out this
50% (n = 8) required inotropic support to maintain stable
hemodynamics (Table 4). The duration of requirement of inotropic
support varied from 24 h to 96 h with mean of 48 h. InotropicTable 5
Surgical management.
Type of procedure Number of patients Percentage (%)
Surgical thrombectomy – –
Pulmonary endartectomy 02 6
IVC ﬁlter 05 16
Table 4
Thrombolytic therapy.
Thrombolytic drug Number of patient Percentage (%)
Streptokinase 06 19
Tenecteplase 12 39
Repeat thrombolysis 03 10
ary thromboembolism: Epidemiology, predictors, and long-term
dx.doi.org/10.1016/j.ihj.2016.08.010
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with massive and sub massive APE (n = 6). One patient developed
profound irreversible shock and respiratory failure requiring
inotropic support and mechanical ventilation. This patient had
massive APE and was treated with thrombolytic therapy. Overall,
10% (n = 3) of the patients with massive APE required mechanical
ventilation with one reported mortality. Bleeding following
intravenous thrombolysis was noted in four patients (13%) with
one patient having massive bleeding episode requiring blood
transfusion.
4. Discussion
The incidence of venous thromboembolism (VTE), which
includes PE and deep venous thrombosis (DVT), has remained
relatively constant, with age- and sex-adjusted rates of 117 cases
per 100,000 person-years.7,8 VTE incidence rises sharply after age
60 in both men and women, with PE accounting for the majority of
the increase.7,8 Acute pulmonary embolism (APE) is a major cause
of death associated with surgery, injury, and medical illnesses. The
mortality rate associated with PE is underappreciated; if untreated,
acute PE is associated with a signiﬁcant mortality rate (as high as
30%) with two of three such people dying of APE die within the ﬁrst
2 h of presentation.1 Mortality rate is up to 8% among those
diagnosed and treated.1 In nearly 25% of patients with PE, the
initial clinical manifestation is sudden death.7
Numerous published studies have shown that the incidence of
ﬁrst-time VTE rises exponentially with age. In the patients
between 50 and 59 years, Anderson reported the incidence of
ﬁrst time VTE of 62 per 100,000, and Silverstein et al. observed a
much higher incidence of 122 per 100,000 among women and
147 per 100,000 among men.8 Between 70 and 79 years age group
Anderson et al. reported 316 cases per 100,000 per year (35%
recurrent); Silverstein et al. reported 440 cases per 100,000 per
year.8 Nordstro¨m et al. overall estimated the cumulative probabil-
ity of developing VTE between ages 50 and 80 at 10.7% for Swedish
men.8 In our study, 71% of the patients belonged to age group 20–
50 years with remaining 29% being over 50 years of age. In those
patients over 50 years the pre-disposing factors leading to APE
could be ascertained in most cases. However, the cause remained
elusive many a times among the group <50 years of age.
Sex predilections for VTE have shown consistent differences in
the incidence of VTE among both the sexes across different subsets
of age groups. Anderson et al. found a similar incidence in both
sexes.9,10 Silverstein et al. reported slightly higher incidence rate
among younger women, and a modest predilection among older
men.8 Cushman et al. reported similar incidences among men and
women except for a 2-fold higher rate in men over age 75.8 The
ICOPER study had male predominance in incidence of pulmonary
thromboembolism.11 Overall our study reported higher incidence
of PTE among the male population (58% in males as against 42% in
females). However, majority of this difference was due to higher
incidence rates of PTE in elderly males. Among the young patient
population of our study, there was no signiﬁcant difference in PTE
incidence in either population group.
Risk factors that have been consistently associated with VTE
include advanced age, prolonged immobility, malignancy, major
surgery, polytrauma, prior VTE, and chronic heart failure. Major
risk factors for pulmonary thromboembolism in our study were
dyslipidemia 42%, prolonged immobilization 35% and DVT 26%.
Due to lack of direct evidence for dyslipidemia it is difﬁcult to
attribute dyslipidemia as risk factor for PTE. However, the effects of
circulating lipid molecules on the vascular endothelium, platelet
function, and coagulation factors in DVT are yet to be elaborated.
Better epidemiologic evidence is required to establish whether
dyslipidemia is a risk factor for venous thromboembolism.Please cite this article in press as: Nagamalesh UM, et al. Acute pulmon
outcome – A single center experience, Indian Heart J. (2016), http://The clinical presentation of PE varies widely with dyspnea being
most frequent presenting symptom. Symptoms vary from severe
dyspnea, cyanosis, or syncope suggesting a massive PE while
pleuritic pain, cough, or hemoptysis indicating a smaller periph-
erally located PE. On physical examination, tachypnea is the most
common sign. All the patients in our study with APE presented
with dyspnea with NYHA Class II or >. Palpitations (71%), chest
pain (29%) and syncope (32%) were the other commonly reported
symptoms. Tachycardia (58%, n = 18) and tachypnea (32%, n = 10)
were the common signs noted. The presence of initial presenting
symptoms and signs from our study were similar to most of the
landmark trials. Following successful therapy, at the end of 1 year
study period majority of the patients reported signiﬁcant
improvement in their symptoms with dyspnea improving from
NYHA Class II or > to NYHA Class I (74%).
RV dysfunction has been shown to predict disease recurrence
and mortality. In a randomized controlled trial, Goldhaber et al.12
found RV function improved at 24 h in 16/18 thrombolysed
patients compared with 8/18 treated with heparin.
On admission 26% of patients were classiﬁed as massive, 32%
were submissive and 41% were low risk. In the ICOPER study, the 90-
day mortality rate for patients with acute PE and systolic blood
pressure <90 mmHg at presentation (108 patients) was 52.4% (95%
conﬁdence interval [CI] 43.3–62.1%).13 Similarly, in the Germany-
based Management Strategy and Prognosis of Pulmonary Embolism
Registry (MAPPET) of 1001 patients with acute PE, in-hospital
mortality was 8.1% for hemodynamically stable patients versus 25%
for those presenting with cardiogenic shock and 65% for those
requiring cardiopulmonary resuscitation.14 In patients with low risk
pulmonary embolism short-term mortality approach 1%. Risk
stratiﬁcation of the patients with APE helped deﬁne the population
suitable for thrombolytic therapy. Data from four registries MAPPET,
ICOPER, RIETE, and, EMPEROR have suggested a trend toward
decrease in all-cause mortality from PE, especially massive PE in
those patients treated with ﬁbrinolysis.15 Konstantinides et al.15
found a 30 day mortality of 4.7% in 169 patients who received
thrombolysis, compared with 11.1% in 550 who were treated with
heparin. Recurrence rates were 7.7% and 18.7% respectively.
In our study, both massive and submissive group received
thrombolytic therapy and low risk patients received low molecular
weight heparin.
Six trials with 481 patients have compared various thrombo-
lytic regimens using rTPA, streptokinase, and urokinase, with rTPA
being delivered over 2 h and urokinase and streptokinase delivered
over 2–24 h.15–21 No agent has proved superior.
Among the 18 (58%) patients in our study, 39% received
tenecteplase and 19% of patients received Streptokinase. In the
tenecteplase group three patients (10%) had failed thrombolysis
that was then treated with streptokinase. All those patients were
maintaining normal pulmonary artery pressure and functional
class at the end of study period. One of the single center study
reported failed thrombolysis in 40 patients (8.2%) among the
488 APE patients who underwent thrombolysis.22 Out of this
14 patients were treated by rescue surgical embolectomy, and
26 were treated by repeat thrombolysis.22 There was no signiﬁcant
difference in the baseline characteristics of the two groups.
However, there was signiﬁcantly more recurrent PEs (fatal and
nonfatal) in the repeat-thrombolysis group (35% versus 0%).22 The
rate of uneventful long-term evolution was the same in the two
groups.22 The questions whether thrombolytic therapy was really
successful in our cohort of patients and whether failed thrombo-
lytic therapy can be treated again with repeat thrombolysis with
the different agent still remains to be answered. The small sample
size of the study made it difﬁcult to address the above issue clearly
although clinically a beneﬁt was noted in patients who were
managed accordingly.ary thromboembolism: Epidemiology, predictors, and long-term
dx.doi.org/10.1016/j.ihj.2016.08.010
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oral anticoagulants for low risk PTE, later developed chronic PTE
with severe PAH with exertional dyspnea Class III (NYHA) and RV
dysfunction. These patients underwent pulmonary endarterecto-
my. They now have exertional dyspnea Class I/II (NYHA) and
normal PA pressures. In a recent series >91.3% of the patients were
in NYHA Functional Class III or IV before procedure and at 1 year
after operation, 91.4% of patients were reclassiﬁed as NYHA
Functional Class I or II.23 In addition, with the elimination of
sustained pressure overload, RV geometry rapidly reverts toward
normal.23
5. Limitations
The small sample size and single center observation were the
main limiting factors of our study. However, successful attempts
were made to elaborately discuss most of the clinico-epidemio-
logic issues concerned with diagnosis and treatment of acute
pulmonary thromboembolism. We also tried to address some of
the key controversial issues concerned with failed thrombolytic
therapy. Also, the role of other surgical and non-surgical
interventions also could not be elaborated completely due to
small sample size again.
Nevertheless, our study shows the potential for a future large
scale multi-center trial in this regard and also gives a basic
framework on which it can be further improvised to understand
the clinico-epidemiologic aspects of APE.
6. Conclusion
APE which was once a disease of the old and frail is now
increasingly becoming common among the young and middle
aged. APE still masquerades itself presenting in various clinical
settings, and posing a great diagnostic challenge to the physician. A
high degree of clinical suspicion with close observation of key
clinical signs is needed to identify this entity. Diagnosed cases need
to be risk stratiﬁed into mild, moderate and massive to plan
appropriate treatment strategy. In case of failed thrombolysis a
repeat thrombolysis can be considered before subjecting to
deﬁnitive surgical approach, however, it needs further validation
from more large scale studies.
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